Circio Holding ASA (“Circio” or “the Company”) announced, on the 26th of August 2026, a research collaboration with Full Circles Therapeutics Inc. (“Full Circles”), a Boston-based developer of non-viral, immune-evasive DNA vector technology. The parties will combine circVec with Full Circles’ C4DNA platform, an engineered circular single-stranded DNA (cssDNA) vector designed to avoid innate immune recognition, to establish a non-viral, non-integrating and immune-silent platform for in vivo cell therapy. Full Circles will design and manufacture C4DNA vectors carrying circVec inserts, which Circio will then evaluate in vitro and in vivo for delivery, expression and immunogenicity. No financial terms are disclosed.
In summary, Analyst Group views the Full Circles collaboration as a technically coherent addition to Circio’s in vivo cell therapy work, pointing toward the combination of durability and re-dosability that in vivo cell therapy has so far lacked. It nevertheless remains preclinical and without disclosed terms, and cell therapy continues to represent an optionality layer rather than a near-term value driver. The H1-26 report will be published on the 31st of August, followed by an R&D and corporate update webcast on the 1st of September, which is set to include new in vivo data in heart and CNS as well as an update on the CAR-T program.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.